The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with all features of the metabolic syndrome. Although deposition of excess triglycerides within liver cells, a hallmark of NAFLD, is associated with a loss of insulin sensitivity, it is not clear which cellular abnormality arises first. We have explored this in mice overexpressing carbohydrate responsive element-binding protein (ChREBP). On a standard diet, mice overexpressing ChREBP remained insulin sensitive, despite increased expression of genes involved in lipogenesis/fatty acid esterification and resultant hepatic steatosis (simple fatty liver). Lipidomic analysis revealed that the steatosis was associated with increased accumulation of monounsaturated fatty acids (MUFAs). In primary cultures of mouse hepatocytes, ChREBP overexpression induced expression of stearoyl-CoA desaturase 1 (Scd1), the enzyme responsible for the conversion of saturated fatty acids (SFAs) into MUFAs. SFA impairment of insulin-responsive Akt phosphorylation was therefore rescued by the elevation of Scd1 levels upon ChREBP overexpression, whereas pharmacological or shRNA-mediated reduction of Scd1 activity decreased the beneficial effect of ChREBP on Akt phosphorylation. Importantly, ChREBP-overexpressing mice fed a high-fat diet showed normal insulin levels and improved insulin signaling and glucose tolerance compared with controls, despite having greater hepatic steatosis. Finally, ChREBP expression in liver biopsies from patients with nonalcoholic steatohepatitis was increased when steatosis was greater than 50% and decreased in the presence of severe insulin resistance. Together, these results demonstrate that increased ChREBP can dissociate hepatic steatosis from insulin resistance, with beneficial effects on both glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In this regard, ChREBP expression in liver biopsies from patients with MASH was observed to be two-fold higher when the histologic steatosis score was greater than 50% compared to those with less than 50%.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
The cited source says what the claim attributes to it.
In the citing paper
“However, it decreased in the presence of severe IR [34,94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Taken together, these findings demonstrate that ChREBP-driven hepatic steatosis can be dissociated from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“genes was achieved by the ΔΔCt method (88).”
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“(91): 0, absent; 1, <5%; 2, 5%–33%; 3, 33%–66%; 4, >66%.”
Signal integration in the endoplasmic reticulum unfolded protein response
Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,296 · cited 1×
“UPR induces transcription of a set of genes whose protein products increase the capacity for protein folding and ER-associated degradation and induces apoptosis when the ER function is severely impaired (41, 42).”
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 11×
“To our knowledge, our work is the first to report that hepatic ChREBP expression varies positively according to the degree of steatosis and inversely to insulin resistance in a cohort of patients with NASH.”
InfluentialDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“Using a multiple-stable-isotope approach, Don-nelly et al. (16) estimated that, of the TG content accounted for in the livers of patients with NAFLD, 60% arose from NEFA, a little over 10% came from the diet, and close to 30% came from de novo lipogenesis, underlying the importance of de novo TG synthesis in the etiol…”
InfluentialNutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075 · cited 17×
“Recent studies have revealed that chronic SFA exposure activates unfolded protein response (UPR) in cultured cells (39, 40).”
InfluentialPGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624 · cited 1×
“In the liver, SIRT1 controls gluconeogenic activity by modulating the acetylation levels of a network of transcription factors and/or coactivators, including PPARGC1A (74–76).”
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · cited 1×
“We also measured the expression of fibroblast growth factor 21 (FGF21), a key metabolic regulator whose expression is regulated via PPAR pathways during states requiring increased fatty acid oxidation (33).”
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322 · cited 2×
“Accumulation of diacylglycerol (DAG) has been report-ed to cause insulin resistance by activating a specific isoform of protein kinase C, PKC ε (8, 31, 32).”
InfluentialPostic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204 · cited 2×
“After the esterification step, TGs can either be stored as lipid droplets within hepatocytes or secreted into the blood as VLDL, but, depending on the nutritional status, they can also be hydrolyzed to allow the channeling of fatty acids toward the β -oxidation pathway (15).”
Self-citationNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 2×
“In addition, it has been recently suggested that the type of fatty acids that are stored in the liver could be more relevant than the degree of steatosis regarding the mechanisms of fatty liver injuries (5, 54).”
Identification and characterization of metabolically benign obesity in humans
Stefan, N. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1609 · Cited by 1,049 · cited 1×
“In agreement with this concept, an identified population of obese humans can stay free of insulin resistance and are metabolically healthy despite morbid obesity (12).”
Lipid Droplets Finally Get a Little R-E-S-P-E-C-T
Farese, R. V., & Walther, T. C. (2009) · Cell · doi:10.1016/j.cell.2009.11.005 · Cited by 1,022 · cited 1×
“To prevent lipotoxicity, cells can enhance incorporation of fatty acids into TGs that are then stored into lipid droplets (55).”
Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X. X., Pandey, S. K., Bhanot, S., Monia, B. P., Li, Y.-X., & Diehl, A. M. (2007) · Hepatology · doi:10.1002/hep.21655 · Cited by 1,015 · cited 2×
“…have favored the concept that the accumulation of intra-hepatic lipids precedes the state of insulin resistance, while others have shown that hepatic TGs themselves are not toxic and may in fact protect the liver from lipotoxicity by buffering the accumulation of deleterious fatty acids (5–8).”
Guillou, H., Zadravec, D., Martin, P. G. P., & Jacobsson, A. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.12.002 · Cited by 865 · cited 1×
“Disruption of elongases, enzymes that are crucial for fatty acids chain length (59), leads to severe metabolic alterations by changing free fatty acids pools (60), while their overexpression increases MUFA accumulation and TG synthesis and storage in lipid droplets.”
Self-citationIizuka, K., Bruick, R. K., Liang, G., Horton, J. D., & Uyeda, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401516101 · Cited by 785 · cited 2×
“The role of ChREBP in the control of glucose and lipid homeostasis is rather complex, since, on one hand, global ChREBP deficiency leads to impaired glucose tolerance and insulin resistance in C57BL/6J mice (25), and, on the other hand, ChREBP deficiency in an obese ob/ob background improves hepatic steatosis and othe…”
Foretz, M., Guichard, C., Ferré, P., & Foufelle, F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12737 · Cited by 747 · cited 7×
“Consistent with this observation, glucokinase (Gck) expression, which is primarily under the transcriptional control of insulin via SREBP-1c (28) remained unchanged under ChREBP overexpression (Figure 1E).”
InfluentialMouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714 · cited 1×
“Dysregulated lipogenesis has been shown to contribute to the pathogenesis of hepatic steatosis in both humans (16, 49) and rodents (50).”
The assessment of insulin resistance in man
Wallace, T. M., & Matthews, D. R. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00745.x · Cited by 677
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Self-citationCellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585 · cited 5×
“Insulin resistance was assessed using the HOMA index as follows: fasting insulin (mU/l) × fasting plasma glucose (mmol/l)/22.5 (90). resistance in both rodents (31, 32) and humans (8).”
InfluentialCryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis
Zhang, E. E., Liu, Y., Dentin, R., Pongsawakul, P. Y., Liu, A. C., Hirota, T., Nusinow, D. A., Sun, X., Landais, S., Kodama, Y., et al. (2010) · Nature Medicine · doi:10.1038/nm.2214 · Cited by 567 · cited 1×
“However, it should be noted that G6pc gene expression, a known target gene of ChREBP (46), was 2-fold increased upon ChREBP overexpression (Figure 9E).”
Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease
Kohjima, M., Enjoji, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., Fujino, T., Yada, M., Yada, R., Harada, N., et al. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.20.3.351 · Cited by 529 · cited 12×
“Excessive accumulation of TGs in hepatocytes is the hallmark of NAFLD.”
InfluentialDissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver
Monetti, M., Levin, M. C., Watt, M. J., Sajan, M. P., Marmor, S., Hubbard, B. K., Stevens, R. D., Bain, J. R., Newgard, C. B., Farese, R. V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.005 · Cited by 511 · cited 2×
“In these studies, overexpression of DGAT2 in liver (9) or blockade of VLDL secretion mediated by MTP inactivation (68) resulted in a clear dissociation between hepatic steatosis and insulin resistance, despite a significant increase in hepatic DAG and ceramide concentrations.”
Samuel, V. T., Liu, Z.-X., Wang, A., Beddow, S. A., Geisler, J. G., Kahn, M., Zhang, X.-M., Monia, B. P., Bhanot, S., & Shulman, G. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30400 · Cited by 497
A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange
Liu, Y., Dentin, R., Chen, D., Hedrick, S., Ravnskjaer, K., Schenk, S., Milne, J., Meyers, D. J., Cole, P., III, J. Y., et al. (2008) · Nature · doi:10.1038/nature07349 · Cited by 484
Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1
Rodgers, J. T., & Puigserver, P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702509104 · Cited by 466 · cited 8×
“Indeed, under both standard diets and HFDs, key components of gluconeogenesis (namely PCK1, PPARGC1A, FOXO1, CRTC2) were decreased upon ChREBP overexpression.”
InfluentialRinella, M. E., & Green, R. M. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.09.020 · Cited by 460
Dentin, R., Pégorier, J.-P., Benhamed, F., Foufelle, F., Ferré, P., Fauveau, V., Magnuson, M. A., Girard, J., & Postic, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312475200 · Cited by 444 · cited 2×
“…the glycolytic enzyme L-pyruvate kinase (L-PK) by glucose and that acting in synergy with sterol regulatory element–binding protein-1c (SREBP-1c) stimulates lipogenic genes (acetyl-CoA carboxylase [ Acaca ] and fatty acid synthase [ FASN ]) in response to insulin and glucose, respectively (17–19).”
Self-citationRole of stearoyl-coenzyme A desaturase in regulating lipid metabolism
Flowers, M. T., & Ntambi, J. M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f9b54d · Cited by 438 · cited 19×
“Inter-estingly, when ChREBP was overexpressed, the deleterious effect of PALM on insulin-mediated phosphorylation of Akt on Ser473 and on Thr308 was prevented (Figure 4A) and was associated with a marked induction of SCD1 (the Δ9-desaturase), the enzyme responsible for the conversion of SFA to MUFA (35) (Figure 4A).”
InfluentialLiver-Specific Inhibition of ChREBP Improves Hepatic Steatosis and Insulin Resistance in ob/ob Mice
Dentin, R., Benhamed, F., Hainault, I., Fauveau, V., Foufelle, F., Dyck, J. R. B., Girard, J., & Postic, C. (2006) · Diabetes · doi:10.2337/db06-0200 · Cited by 433
Self-citationCarbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription
Ishii, S., IIzuka, K., Miller, B. C., & Uyeda, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405238101 · Cited by 416
Miyazaki, M., Flowers, M. T., Sampath, H., Chu, K., Otzelberger, C., Liu, X., & Ntambi, J. M. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.014 · Cited by 414 · cited 1×
“Among desaturases, SCD1 is particularly critical to convert SFAs (mainly PALM C16:0 and stearate C18:0) into MUFAs (palmitoleate C16:1n-7 and oleate C18:1n-9) in the liver (38).”
Kabashima, T., Kawaguchi, T., Wadzinski, B. E., & Uyeda, K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730817100 · Cited by 401 · cited 1×
“The activation of ChREBP in response to glucose involves several posttranslational modifications, such as O-GlcNAcylation (20), acetylation on specific lysine (Lys672) (21), and dephosphorylation on serine (Ser) and threonine (Thr) residues (22).”
Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2
Dentin, R., Liu, Y., Koo, S.-H., Hedrick, S., Vargas, T., Heredia, J., Yates, J., & Montminy, M. (2007) · Nature · doi:10.1038/nature06128 · Cited by 400 · cited 5×
“Indeed, under both standard diets and HFDs, key components of gluconeogenesis (namely PCK1, PPARGC1A, FOXO1, CRTC2) were decreased upon ChREBP overexpression.”
InfluentialHepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease
Li, Z. Z., Berk, M., McIntyre, T. M., & Feldstein, A. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807616200 · Cited by 400 · cited 10×
“To our knowledge, our work is the first to report that hepatic ChREBP expression varies positively according to the degree of steatosis and inversely to insulin resistance in a cohort of patients with NASH.”
InfluentialNonalcoholic fatty liver disease: A review of current understanding and future impact
Charlton, M. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00440-9 · Cited by 350 · cited 1×
“Excessive accumulation of TGs in hepatocytes is the hallmark of NAFLD (3, 4).”
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis
Semple, R. K., Sleigh, A., Murgatroyd, P. R., Adams, C. A., Bluck, L., Jackson, S., Vottero, A., Kanabar, D., Charlton-Menys, V., Durrington, P., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37432 · Cited by 344 · cited 1×
“In contrast, steatosis is indicative of the persistent effect of insulin on the lipogenic pathway (de novo lipogenesis) in the liver (81) and of adipose tissue resistance, leading to increased levels of NEFA and lipoprotein remnants being captured by the liver.”
Hepatic Glucose Sensing via the CREB Coactivator CRTC2
Dentin, R., Hedrick, S., Xie, J., Yates, J., & Montminy, M. (2008) · Science · doi:10.1126/science.1151363 · Cited by 319
It's Not How Fat You Are, It's What You Do with It That Counts
Virtue, S., & Vidal-Puig, A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060237 · Cited by 312 · cited 1×
“Because fatty acids have been shown to serve as signaling molecules, exerting either beneficial (i.e., lipokines) or detrimental (i.e., lipotoxicity) metabolic outcomes (8, 29, 30), lipidomic analysis was performed in livers of ChREBP mice.”
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312 · cited 1×
“All features of the metabolic syndrome, including obesity, type 2 diabetes, arterial hypertension, and hyperlipidemia (in the form of elevated triglyceride [TG] levels), are associated with NAFLD/NASH (2).”
Kantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., Häring, H.-U., et al. (2009) · Diabetes · doi:10.2337/db09-0279 · Cited by 303
Bricambert, J., Miranda, J., Benhamed, F., Girard, J., Postic, C., & Dentin, R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41624 · Cited by 300 · cited 3×
“The activation of ChREBP in response to glucose involves several posttranslational modifications, such as O-GlcNAcylation (20), acetylation on specific lysine (Lys672) (21), and dephosphorylation on serine (Ser) and threonine (Thr) residues (22).”
Self-citationDecrease in Membrane Phospholipid Unsaturation Induces Unfolded Protein Response
Ariyama, H., Kono, N., Matsuda, S., Inoue, T., & Arai, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.126870 · Cited by 287 · cited 3×
“Our in vitro experiments support studies showing that lipotoxicity and ER stress are almost exclusively attributed to SFA (6, 39) and that they can be prevented by oleate and/or palmitoleate incubation (61, 62).”
Miyazaki, M., Dobrzyn, A., Man, W. C., Chu, K., Sampath, H., Kim, H.-J., & Ntambi, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402781200 · Cited by 283 · cited 1×
“On one hand, inactivation of SCD1 in liver prevents fatty liver, insulin resistance, and obesity induced by high carbohydrate feeding (63) but, on the other hand, worsens diabetes in ob/ob mice (64).”
Hepatic triacylglycerol accumulation and insulin resistance
Nagle, C. A., Klett, E. L., & Coleman, R. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800053-jlr200 · Cited by 272 · cited 1×
“This discrepancy might be explained if different pools of DAG and ceramide exist within the hepatocytes, as previously suggested in muscle cells (69), with only certain pools being able to regulate inhibitors of insulin signaling (70).”
Louvet, A., Teixeira-Clerc, F., Chobert, M.-N., Deveaux, V., Pavoine, C., Zimmer, A., Pecker, F., Mallat, A., & Lotersztajn, S. (2011) · Hepatology · doi:10.1002/hep.24524 · Cited by 261
Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis
Akazawa, Y., Cazanave, S., Mott, J. L., Elmi, N., Bronk, S. F., Kohno, S., Charlton, M. R., & Gores, G. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.003 · Cited by 252 · cited 1×
“Our in vitro experiments support studies showing that lipotoxicity and ER stress are almost exclusively attributed to SFA (6, 39) and that they can be prevented by oleate and/or palmitoleate incubation (61, 62).”
Lipid Mediators of Insulin Resistance
Holland, W. L., Knotts, T. A., Chavez, J. A., Wang, L.-P., Hoehn, K. L., & Summers, S. A. (2007) · Nutrition Reviews · doi:10.1301/nr.2007.jun.s39-s46 · Cited by 249
Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice
Moon, Y.-A., Hammer, R. E., & Horton, J. D. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800383-jlr200 · Cited by 236
Koliwad, S. K., Streeper, R. S., Monetti, M., Cornelissen, I., Chan, L., Terayama, K., Naylor, S., Rao, M., Hubbard, B., & Farese, R. V. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36066 · Cited by 233 · cited 1×
“According to this hypothesis, it was reported that overexpression of DGAT1 improves storage of neutral TG within lipid droplets, thereby reducing deleterious lipid species, inflammation, and insulin resistance in macrophages and/or muscle cells (56–58).”
Recent advances in nonalcoholic fatty liver disease
Cheung, O., & Sanyal, A. J. (2009) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283294a18 · Cited by 219 · cited 2×
“Discussion NAFLD is an increasing health concern now considered as a component of the metabolic syndrome (1).”
Barrans, A., Collet, X., Barbaras, R., Jaspard, B., Manent, J., Vieu, C., Chap, H., & Perret, B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78162-9 · Cited by 217
O-GlcNAcylation Increases ChREBP Protein Content and Transcriptional Activity in the Liver
Guinez, C., Filhoulaud, G., Rayah-Benhamed, F., Marmier, S., Dubuquoy, C., Dentin, R., Moldes, M., Burnol, A.-F., Yang, X., Lefebvre, T., et al. (2011) · Diabetes · doi:10.2337/db10-0452 · Cited by 211
Self-citationChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver
Denechaud, P.-D., Bossard, P., Lobaccaro, J.-M. A., Millatt, L., Staels, B., Girard, J., & Postic, C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34314 · Cited by 203 · cited 2×
“Although we recently reported the importance of ChREBP acetylation and O-GlcNAcylation in response to glucose (20, 21), we also described the relevance of modulating the phosphorylation of Ser196 residue for ChREBP localization and/or activity in response to glucose and glucagon (23, 24).”
Self-citationIizuka, K., Miller, B., & Uyeda, K. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00027.2006 · Cited by 195 · cited 1×
“…on one hand, global ChREBP deficiency leads to impaired glucose tolerance and insulin resistance in C57BL/6J mice (25), and, on the other hand, ChREBP deficiency in an obese ob/ob background improves hepatic steatosis and other related metabolic alterations, including insulin resistance (26, 27).”
CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis
Cazanave, S. C., Elmi, N. A., Akazawa, Y., Bronk, S. F., Mott, J. L., & Gores, G. J. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00091.2010 · Cited by 189 · cited 1×
“Our in vitro experiments support studies showing that lipotoxicity and ER stress are almost exclusively attributed to SFA (6, 39) and that they can be prevented by oleate and/or palmitoleate incubation (61, 62).”
Direct Role of ChREBP·Mlx in Regulating Hepatic Glucose-responsive Genes
Ma, L., Tsatsos, N. G., & Towle, H. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413063200 · Cited by 189 · cited 10×
“ChREBP-z isoform mutated on Ser196 and Thr666 (19) was subcloned”
InfluentialGlucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes
Iizuka, K., Takeda, J., & Horikawa, Y. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.053 · Cited by 187 · cited 6×
“FGF21 concentrations were measured using the Rat/ Mouse FGF-21 ELISA Kit (EZRMFGF21-26K, Millipore).”
InfluentialDentin, R., Tomas-Cobos, L., Foufelle, F., Leopold, J., Girard, J., Postic, C., & Ferré, P. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.019 · Cited by 177 · cited 2×
“Although we recently reported the importance of ChREBP acetylation and O-GlcNAcylation in response to glucose (20, 21), we also described the relevance of modulating the phosphorylation of Ser196 residue for ChREBP localization and/or activity in response to glucose and glucagon (23, 24).”
Self-citationCREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability
Noriega, L. G., Feige, J. N., Canto, C., Yamamoto, H., Yu, J., Herman, M. A., Mataki, C., Kahn, B. B., & Auwerx, J. (2011) · EMBO reports · doi:10.1038/embor.2011.151 · Cited by 172 · cited 4×
“In agreement with this hypothesis, acetylation levels of PPARGC1A were decreased by 50% in livers of ChREBP knockout mice (73).”
InfluentialNonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance
Abdelmalek, M. F., & Diehl, A. M. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.001 · Cited by 171 · cited 11×
“Excessive accumulation of TGs in hepatocytes is the hallmark of NAFLD.”
InfluentialChen, C., Shah, Y. M., Morimura, K., Krausz, K. W., Miyazaki, M., Richardson, T. A., Morgan, E. T., Ntambi, J. M., Idle, J. R., & Gonzalez, F. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.003 · Cited by 167 · cited 1×
“Interestingly, oleic acid feeding and in vivo SCD1-rescued expression alleviates the dextran sulfate sodium–induced phenotype, suggesting that SCD1 and its related lipid species may serve as potential targets for intervention and/or treatment of inflammatory diseases (66).”
The role of stearoyl‐CoA desaturase in obesity, insulin resistance, and inflammation
Sampath, H., & Ntambi, J. M. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06303.x · Cited by 164 · cited 1×
“Acyl-CoA desaturases, such as SCD1 (37), introduce a double bond at a specific position on the acyl chain of fatty acids, thereby influencing several structural, metabolic, and signaling properties of the fatty acid or of the fatty acid containing lipids.”
Minehira, K., Young, S. G., Villanueva, C. J., Yetukuri, L., Oresic, M., Hellerstein, M. K., Farese, R. V., Horton, J. D., Preitner, F., Thorens, B., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800248-jlr200 · Cited by 164
Son, N.-H., Yu, S., Tuinei, J., Arai, K., Hamai, H., Homma, S., Shulman, G. I., Abel, E. D., & Goldberg, I. J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40905 · Cited by 159
Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter
Lodhi, I. J., Wei, X., & Semenkovich, C. F. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.09.002 · Cited by 151 · cited 3×
“Our results support the novel concept of lipoexpediency (in opposition to lipotoxicity) recently proposed by Semenkovich and colleagues (13).”
Jeong, Y.-S., Kim, D., Lee, Y. S., Kim, H.-J., Han, J.-Y., Im, S.-S., Chong, H. K., Kwon, J.-K., Cho, Y.-H., Kim, W. K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022544 · Cited by 149 · cited 2×
“…products (i.e., MUFA) (Figure 2G) was observed upon ChREBP overexpression in liver under both standard and HFDs. Interestingly, both SCD1 and Elovl6 were identified among 700 other direct target genes of ChREBP in a genome-wide scale analysis performed in HepG2 cells using ChIP sequencing (53).”
Flowers, J. B., Rabaglia, M. E., Schueler, K. L., Flowers, M. T., Lan, H., Keller, M. P., Ntambi, J. M., & Attie, A. D. (2007) · Diabetes · doi:10.2337/db06-1142 · Cited by 148 · cited 1×
“On one hand, inactivation of SCD1 in liver prevents fatty liver, insulin resistance, and obesity induced by high carbohydrate feeding (63) but, on the other hand, worsens diabetes in ob/ob mice (64).”
Lipid Mediators of Insulin Resistance
Holland, W. L., Knotts, T. A., Chavez, J. A., Wang, L.-P., Hoehn, K. L., & Summers, S. A. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00327.x · Cited by 139 · cited 1×
“Because fatty acids have been shown to serve as signaling molecules, exerting either beneficial (i.e., lipokines) or detrimental (i.e., lipotoxicity) metabolic outcomes (8, 29, 30), lipidomic analysis was performed in livers of ChREBP mice.”
Recent advances in nonalcoholic fatty liver disease
Cheung, O., & Sanyal, A. J. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328337b0c4 · Cited by 139
Wu, C., Kang, J., Peng, L.-J., Li, H., Khan, S. A., Hillard, C. J., Okar, D. A., & Lange, A. J. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.07.003 · Cited by 109 · cited 1×
“Indeed, it has been previously reported that enhancing glycolytic rates through GCK in obese mice had beneficial influences on overall whole-body energy balance, including glucose tolerance (71).”
Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases
Kharitonenkov, A., & Shanafelt, A. B. (2008) · BioDrugs · doi:10.2165/00063030-200822010-00004 · Cited by 104 · cited 1×
“Because Fgf21 gene expression is under the transcriptional control of ChREBP (34) and because FGF21 has beneficial effects on plasma glucose and lipid profiles in diabetic rodents (47), mRNA and cir-Figure”
Hadri, K. E., Glorian, M., Monsempes, C., Dieudonné, M.-N., Pecquery, R., Giudicelli, Y., Andreani, M., Dugail, I., & Fève, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312875200 · Cited by 101
Modulation of intracellular calcium transients and dopamine release by neuropeptide Y in PC-12 cells
Chen, X., & Westfall, T. C. (1994) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1994.266.3.c784 · Cited by 91
Glucose activation of ChREBP in hepatocytes occurs via a two-step mechanism
Tsatsos, N. G., & Towle, H. C. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.029 · Cited by 88 · cited 1×
“Although it was previously reported that mutations of Ser196 and/or Thr666 may not result in a constitutively active form of ChREBP (51), we report here that ChREBP target genes were efficiently induced under both substrate abundance (standard CD and HFD) and fasting conditions.”
Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis
Flamment, M., Kammoun, H. L., Hainault, I., Ferré, P., & Foufelle, F. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283395e5c · Cited by 82 · cited 1×
“UPR induces transcription of a set of genes whose protein products increase the capacity for protein folding and ER-associated degradation and induces apoptosis when the ER function is severely impaired (41, 42).”
de Luis, O., Valero, M. C., & Jurado, L. A. P. (2000) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200435 · Cited by 81 · cited 1×
“Lastly, the human homolog of ChREBP, WBSCR14 (also known as MondoB), is located on a chromosomal region deleted in the WilliamsBeuren syndrome, a syndrome characterized in 75% of the cases by severe glucose intolerance (72).”
ChREBP expression in the liver, adipose tissue and differentiated preadipocytes in human obesity
del Pozo, C. H., Vesperinas, G., Rubio, M. Á., Corripio‐Sánchez, R., García, A. J. T., Obregón, M.-J., & Calvo, R. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.07.016 · Cited by 77 · cited 1×
“Interestingly, ChREBP expression (mRNA and protein content) was recently found to be elevated (a 2-fold increase) in livers of obese patients (79).”
Nontriglyceride Hepatic Lipotoxicity: The New Paradigm for the Pathogenesis of NASH
Neuschwander‐Tetri, B. A. (2010) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0083-6 · Cited by 68
Carobbio, S., Rodriguez-Cuenca, S., & Vidal-Puig, A. (2011) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32834ad966 · Cited by 64 · cited 3×
“However, over accumulation of fatty acids can be considered toxic/deleterious (14, 54).”
Oleate-enriched diet improves insulin sensitivity and restores muscle protein synthesis in old rats
Tardif, N., Salles, J., Landrier, J., Mothe‐Satney, I., Guillet, C., Vaysse, C., Combaret, L., Giraudet, C., Patrac, V., Bertrand‐Michel, J., et al. (2011) · Clinical Nutrition · doi:10.1016/j.clnu.2011.05.009 · Cited by 51 · cited 1×
“In agreement with this concept, a recent study reports that consumption of an oleicenriched diet improves insulin sensitivity and decreases inflammation in muscles from aged rats (67).”
Self-citationTimmers, S., den Bosch, J. D. V., Towler, M. C., Schaart, G., Moonen‐Kornips, E., Mensink, R. P., Hesselink, M. K. C., Hardie, D. G., & Schrauwen, P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m000992 · Cited by 44 · cited 1×
“According to this hypothesis, it was reported that overexpression of DGAT1 improves storage of neutral TG within lipid droplets, thereby reducing deleterious lipid species, inflammation, and insulin resistance in macrophages and/or muscle cells (56–58).”
Reduced levels of SCD1 accentuate palmitate-induced stress in insulin-producing β-cells
Thörn, K., Hovsepyan, M., & Bergsten, P. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-108 · Cited by 43 · cited 2×
“As previously described (40), chop expression was increased in cells incubated with PALM (Figure 6C).”
Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis
Buettner, R., Ottinger, I., Schölmerich, J., & Bollheimer, L. C. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2003 · Cited by 40 · cited 1×
“Such findings suggest that hepatic steatosis is not necessarily associated with insulin resistance (9–11).”
Coupled assay of sphingomyelin and ceramide molecular species by gas liquid chromatography
Vieu, C., Tercé, F., Chevy, F., Rolland, C., Barbaras, R., Chap, H., Wolf, C., Perret, B., & Collet, X. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30157-7 · Cited by 39
Paton, C. M., & Ntambi, J. M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00388.2010 · Cited by 38 · cited 3×
“To better define the contribution of SCD1 to the ChREBP-mediated protective effects on Akt phosphorylation, we pharmacologically inhibited SCD1 activity (SCD1inhib), as described previously (36).”
InfluentialCarré, N., Caüzac, M., Girard, J. R., & Burnol, A. (2008) · Endocrinology · doi:10.1210/en.2007-1196 · Cited by 26 · cited 1×
“Hepatic glucose production was measured after PCA neutralization as previously described (84).”
Self-citationGuha, P., Aneja, K. K., Shilpi, R. Y., & Haldar, D. (2009) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2009.07.027 · Cited by 18 · cited 1×
“Aside from previously known targets of ChREBP, such as L-PK, ACACA, FASN, GPAT, G6PC, and FGF21 (19, 34, 52), our results reveal that SCD1 and Elovl6 are key ChREBP target genes.”
Insulin increases a biochemically distinct pool of diacylglycerol in the rat soleus muscle
Chen, K. S., Heydrick, S. J., Brown, M. L., Friel, J., & Ruderman, N. B. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.3.e479 · Cited by 17 · cited 1×
“This discrepancy might be explained if different pools of DAG and ceramide exist within the hepatocytes, as previously suggested in muscle cells (69), with only certain pools being able to regulate inhibitors of insulin signaling (70).”
Research works printed but not linked: 2
- Denechaud, 2008, J Clin Invest., 118, 956
- Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes . 2006;55(8):2159-2170. · DOI · Paper page
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
“Yet the ChREBP-overexpressing mice had normal glucose and insulin tolerance on regular chow diet and were even protected from HFD-induced defects in glucose tolerance and hepatic insulin signaling (49).”
BackgroundEnergy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
“Conversely, overexpression of ChREBP in the liver causes hepatic steatosis without concomitant insulin resistance (13).”
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
“High ChREBP expression was found in biopsies from NASH patients, but levels declined in patients with severe insulin resistance, indicating that ChREBP may segregate hepatic steatosis from insulin resistance [52].”
BackgroundInfluential
Metadata
- Authors
- Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., Girard, J., Guillou, H., & Postic, C.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital Saint-Antoine (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Toxicologie Alimentaire (FR)
- Institut Cochin (FR)
- Corresponding author
- Postic, Catherine
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2012-06-01
- Volume
- 122
- Issue
- 6
- Pages
- 2176-2194
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3366390
- OpenAlex
- W2117220292
- Cited by
- 408
- References
- 94
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 22 · 2023: 35 · 2022: 27 · 2021: 28 · 2020: 34 · 2019: 23 · 2018: 25 · 2017: 35 · 2016: 27 · 2015: 30 · 2014: 41 · 2013: 27 · 2012: 13
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL Portal Artxiker (Hindustan Aeronautics Limited (India)) (submittedVersion)
- Funders
- European Commission
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale (U1016)
- Association Française pour l'Etude du Foie (AFEF-2008)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- ChREBP, carbohydrate-responsive element-binding protein, hepatic steatosis, insulin resistance, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, lipogenesis, fatty acid esterification, stearoyl-CoA desaturase 1, monounsaturated fatty acids, Akt phosphorylation, insulin signaling, glucose tolerance, high-fat diet, lipidomics, hepatocytes
- MeSH terms
- Animals, Fatty Acids, Monounsaturated, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Nuclear Proteins, Phosphorylation, Stearoyl-CoA Desaturase, Transcription Factors, Metabolic Syndrome, Lipogenesis, Proto-Oncogene Proteins c-akt, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.